Pazopanib for the treatment of soft-tissue sarcoma
Pierre Heudel,1 Philippe Cassier,1 Olfa Derbel,1 Armelle Dufresne,1 Pierre Meeus,2 Philippe Thiesse,3 Dominique Ranchère-Vince,4 Jean Yves Blay,1 Isabelle Ray-Coquard1,51Department of Medical Oncology, 2Department of Surgical Oncology, 3Department of Radiology, 4Department of Patholog...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2012-10-01
|
| Series: | Clinical Pharmacology: Advances and Applications |
| Online Access: | http://www.dovepress.com/pazopanib-for-the-treatment-of-soft-tissue-sarcoma-a11370 |
| _version_ | 1818858130118803456 |
|---|---|
| author | Heudel P Cassier P Derbel O Dufresne A Meeus P Thiesse P Ranchère-Vince D Blay JY Ray-Coquard I |
| author_facet | Heudel P Cassier P Derbel O Dufresne A Meeus P Thiesse P Ranchère-Vince D Blay JY Ray-Coquard I |
| author_sort | Heudel P |
| collection | DOAJ |
| description | Pierre Heudel,1 Philippe Cassier,1 Olfa Derbel,1 Armelle Dufresne,1 Pierre Meeus,2 Philippe Thiesse,3 Dominique Ranchère-Vince,4 Jean Yves Blay,1 Isabelle Ray-Coquard1,51Department of Medical Oncology, 2Department of Surgical Oncology, 3Department of Radiology, 4Department of Pathology, Leon Berard Center, Lyon, 5EAM 4128 Sante-Individu-Societe, Lyon University, Lyon, FranceAbstract: Pazopanib is a multikinase inhibitor which potently inhibits the activity of major receptor tyrosine kinases, including vascular endothelial growth factor receptor-1, vascular endothelial growth factor receptor-2, vascular endothelial growth factor receptor-3, platelet-derived growth factor receptor-a, platelet-derived growth factor receptor-a, and c-Kit. Approved by the Food and Drug Administration in 2009 in the United States for the treatment of metastatic renal cell carcinoma, pazopanib has been tested in advanced or metastatic soft-tissue sarcoma. Unlike other tyrosine kinase inhibitors, a statistically significant efficacy in phase II but also in randomized phase III studies has been shown. In comparison with sunitinib or sorafenib, pazopanib has a similar toxicity profile and is generally well tolerated. This review details the development of this new therapeutic class in the treatment of metastatic soft-tissue sarcomas.Keywords: soft-tissue sarcoma, pazopanib, tyrosine kinase inhibitor |
| first_indexed | 2024-12-19T08:51:23Z |
| format | Article |
| id | doaj.art-b1967181c70045e88f03c8d5e700d598 |
| institution | Directory Open Access Journal |
| issn | 1179-1438 |
| language | English |
| last_indexed | 2024-12-19T08:51:23Z |
| publishDate | 2012-10-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Clinical Pharmacology: Advances and Applications |
| spelling | doaj.art-b1967181c70045e88f03c8d5e700d5982022-12-21T20:28:43ZengDove Medical PressClinical Pharmacology: Advances and Applications1179-14382012-10-012012default6570Pazopanib for the treatment of soft-tissue sarcomaHeudel PCassier PDerbel ODufresne AMeeus PThiesse PRanchère-Vince DBlay JYRay-Coquard IPierre Heudel,1 Philippe Cassier,1 Olfa Derbel,1 Armelle Dufresne,1 Pierre Meeus,2 Philippe Thiesse,3 Dominique Ranchère-Vince,4 Jean Yves Blay,1 Isabelle Ray-Coquard1,51Department of Medical Oncology, 2Department of Surgical Oncology, 3Department of Radiology, 4Department of Pathology, Leon Berard Center, Lyon, 5EAM 4128 Sante-Individu-Societe, Lyon University, Lyon, FranceAbstract: Pazopanib is a multikinase inhibitor which potently inhibits the activity of major receptor tyrosine kinases, including vascular endothelial growth factor receptor-1, vascular endothelial growth factor receptor-2, vascular endothelial growth factor receptor-3, platelet-derived growth factor receptor-a, platelet-derived growth factor receptor-a, and c-Kit. Approved by the Food and Drug Administration in 2009 in the United States for the treatment of metastatic renal cell carcinoma, pazopanib has been tested in advanced or metastatic soft-tissue sarcoma. Unlike other tyrosine kinase inhibitors, a statistically significant efficacy in phase II but also in randomized phase III studies has been shown. In comparison with sunitinib or sorafenib, pazopanib has a similar toxicity profile and is generally well tolerated. This review details the development of this new therapeutic class in the treatment of metastatic soft-tissue sarcomas.Keywords: soft-tissue sarcoma, pazopanib, tyrosine kinase inhibitorhttp://www.dovepress.com/pazopanib-for-the-treatment-of-soft-tissue-sarcoma-a11370 |
| spellingShingle | Heudel P Cassier P Derbel O Dufresne A Meeus P Thiesse P Ranchère-Vince D Blay JY Ray-Coquard I Pazopanib for the treatment of soft-tissue sarcoma Clinical Pharmacology: Advances and Applications |
| title | Pazopanib for the treatment of soft-tissue sarcoma |
| title_full | Pazopanib for the treatment of soft-tissue sarcoma |
| title_fullStr | Pazopanib for the treatment of soft-tissue sarcoma |
| title_full_unstemmed | Pazopanib for the treatment of soft-tissue sarcoma |
| title_short | Pazopanib for the treatment of soft-tissue sarcoma |
| title_sort | pazopanib for the treatment of soft tissue sarcoma |
| url | http://www.dovepress.com/pazopanib-for-the-treatment-of-soft-tissue-sarcoma-a11370 |
| work_keys_str_mv | AT heudelp pazopanibforthetreatmentofsofttissuesarcoma AT cassierp pazopanibforthetreatmentofsofttissuesarcoma AT derbelo pazopanibforthetreatmentofsofttissuesarcoma AT dufresnea pazopanibforthetreatmentofsofttissuesarcoma AT meeusp pazopanibforthetreatmentofsofttissuesarcoma AT thiessep pazopanibforthetreatmentofsofttissuesarcoma AT ranchampegraverevinced pazopanibforthetreatmentofsofttissuesarcoma AT blayjy pazopanibforthetreatmentofsofttissuesarcoma AT raycoquardi pazopanibforthetreatmentofsofttissuesarcoma |